ACOSOG Non Competing Renewal

ACOSOG 非竞争性续展

• 批准号: 7758835
• 负责人: DAVID M. OTA
• 金额: $ 356.02万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-05-15 至 2010-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7758835
• 关键词: Address; Advocate; American College of Surgeons Oncology Group; Basic Science; Biometry; Breast; Caring; Chest; Clinical Cancer Center; Clinical Research; Clinical Trials; Conduct Clinical Trials; Development; Discipline; Discipline of Nursing; Disease; Ensure; Esophagus; Feedback; Image; Individual; Investigation; Leadership; Lung; Mission; Molecular Profiling; Monitor; Morbidity - disease rate; Neoadjuvant Therapy; Operative Surgical Procedures; Outcome; Pancreas; Patients; Peer Review; Process; Protocols documentation; Quality of life; Rectum; Research Infrastructure; Research Institute; Research Personnel; Review Committee; Risk; Sampling; Science; Stratification; Surgical Oncology; Testing; Toxic effect; Universities; Washington; Work; base; cancer care; disability; gastrointestinal; improved; innovation; member; molecular imaging; novel; operation; programs; response

The American College of Surgeons Oncology Group (ACOSOG) is dedicated to improving the care of the surgical oncology patient through an innovative clinical research program addressing three specific aims: 1. To test novel therapies that may increase response rates and cure rates and reduce morbidities and disabilities associated with cancer care. 2. To conduct basic science studies in conjunction with clinical trials to better understand the biologic basis of diseases and treatments. 3. To support individual members and investigator networks to accrue patients to trials and fulfill the scientific mission of ACOSOG. The scientific portfolio of ACOSOG is focused on investigations specific to molecular and image profiling, neoadjuvant therapies, and targeted or novel surgical therapies. There are four scientific committees including a Basic Science Committee and three disease committees: Breast, Gastrointestinal (GIST, pancreas, and rectum) and Thoracic (lung and esophagus). Three scientific aims are described for ACOSOG trials including: a) to enhance risk stratification by increasing the accuracy of prognostication through imaging and molecular profiling; b) to improve overall response rates and monitor individual responses through the application of neoadjuvant therapies; and c) to investigate novel, targeted, and surgical therapies to maintain oncologic outcomes while Individualized Response Monll reducing toxicities and disabilities thereby improving quality of life. To set the scientific agenda of ACOSOG, the disease committees work with the Basic Science Committee to ensure, where appropriate, the development of science-driven trials. The scientific committees also work closely with the administrative committees & the Peer-Review and Prioritization Committee to ensure membership support as well as prioritization, coordination, and quality science. All disciplines as well as Nursing & Patient Advocates are represented and provide protocol feedback through the Peer-Review Committee process. The Basic Science Committee & ACOSOG Biospecimen Bank ensure the appropriate acquisition and storage of samples to conduct the scientific studies integrated into each clinical trial. To accomplish the scientific aims, ACOSOG conducts clinical trials using an infrastructure consisting of five critical components, including the: 1) Administrative Coordinating Center (ACC or Operations Office) located in Durham, NC within the Duke Clinical Research Institute; 2) Biostatistics, located in Rochester, MN, within the Mayo Clinical Cancer Center; 3) Leadership, both scientific and organizational; 4) Membership and Networks; and 5) the Biospecimen Bank located in St. Louis, MO, within Washington University.

美国外科医生学会肿瘤组（ACOSOG）致力于改善外科手术的护理， 通过创新的临床研究计划，为肿瘤患者提供三个具体目标： 1.测试可能增加反应率和治愈率并减少发病率和残疾的新疗法 与癌症护理有关。 2.结合临床试验进行基础科学研究，以更好地了解疾病的生物学基础 和治疗。 3.支持个人成员和研究者网络招募患者参加试验并完成科学使命 关于ACOSOG ACOSOG的科学组合专注于特定于分子的研究 和图像分析、新辅助治疗和靶向或新型外科治疗。 有四个科学委员会，包括一个基础科学委员会和三个 疾病委员会：乳腺、胃肠道（GIST、胰腺和直肠）和 胸部（肺和食管）。描述了ACOSOG试验的三个科学目标 包括：a）通过提高预测的准确性来加强风险分层 通过成像和分子分析; B）提高总体响应率， 通过应用新辅助疗法监测个体反应;以及c） 研究新的、靶向的和手术治疗，以维持肿瘤学结局， 个性化 响应Monll 减少毒性和残疾，从而提高生活质量。 为了制定ACOSOG的科学议程，疾病委员会与基础科学委员会合作， 酌情确保开展科学驱动的试验。科学委员会还与 行政委员会和同行审查和优先事项委员会，以确保成员的支持，以及 优先化、协调和质量科学。所有学科以及护理和病人倡导者是 代表并通过同行评审委员会流程提供方案反馈。基础科学 委员会和ACOSOG生物样本库确保适当采集和储存样本，以进行 将科学研究融入每项临床试验。 为了实现科学目标，ACOSOG使用由以下五个关键组成的基础设施进行临床试验： 包括：1）位于北卡罗来纳州达勒姆的行政协调中心（ACC或运营办公室） 在杜克临床研究所内; 2）生物统计学，位于罗切斯特，明尼苏达州，在马约临床癌症 中心; 3）科学和组织领导力; 4）会员和网络;以及5）生物标本库 位于密苏里州圣路易斯市，在华盛顿大学内。